Pompano Beach, FL, Oct. 01, 2018 — BioStem Life Sciences (“Life Sciences” or the “Company”), a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM), a Company focused on the development of the highest quality placental-based amniotic tissue products, whose mission is to create a new paradigm of healthcare, using breakthrough therapies that treat patients who otherwise are without effective treatment options, announced today that it has entered the market with four placental-derived tissue products for multiple indications within the ophthalmology, orthopedic and advanced wound care markets. [Read more…]
Sponsored Content: Press releases may be published as paid or sponsored content. The issuers of these press releases are solely responsible for their content. BioInformant is not responsible for the accuracy or claims made in these announcements and does not endorse the views expressed by their issuers.
Exosome Start-up ExoCoBio Inc. raises $26.7M in Series B Funding
-
ExoCoBio is the 4th largest funded exosome startup in the world
-
ExoCoBio is using the funding to advance its exosome pharmaceutical R&D and cosmeceutical business
SEOUL, South Korea, Sept. 12, 2018 — ExoCoBio Inc. announced that it recently raised about $27 million in its series B funding. Top tier Korean investors participated in this round, including Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum technology Investment.
[Read more…]
Introducing WellSky — A New Approach to Health and Community Care
Mediware Information Systems, Kinnser Software, and More Than 30 Leaders in Health IT Unite Under One New Brand, Providing Integrated Health and Community Care Solutions for Millions of Patients
Novartis Receives Health Canada Approval of its CAR-T cell therapy, Kymriah™
- Kymriah, the first chimeric antigen receptor T cell (CAR-T) therapy approved in Canada, is manufactured individually for each patient
- Novartis is working with qualified treatment centres to prepare for the delivery of this treatment for relapsed/refractory (r/r) pediatric and young adult B-cell ALL and adult r/r DLBCL indications
DORVAL, QC, Sept. 6, 2018 – Novartis is pleased to announce that following a Priority Review, Health Canada has approved Kymriah™ (tisagenlecleucel/ CTL019) the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in Canada.
Kymriah, a CD19-directed genetically modified autologous T-cell immunocellular therapy, is approved to treat two life-threatening cancers that have limited treatment options and historically poor outcomes, demonstrating the critical need for new therapies for these patients. [Read more…]
Celularity Acquires CariCord, Adds Biosourcing Assets, Establishes Relationship with ClinImmune Labs
WARREN, N.J., Aug. 31, 2018 — Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood bank established by the University of Colorado and ClinImmune Labs. Through its exclusive ClinImmune Labs relationship, CariCord is the first, and so far the only family cord blood bank to operate inside a FDA Licensed Laboratory. ClinImmune Labs is an academic component of the School of Medicine at the University of Colorado at Denver and Health Sciences Center. Financial details of the transaction were not disclosed. [Read more…]
- « Previous Page
- 1
- …
- 103
- 104
- 105
- 106
- 107
- …
- 118
- Next Page »